ストックスクリーナーアプリを入手
1.68
2.89%
-0.05
前日終値:
$1.73
開ける：
$1.72
24時間の取引高:
88,872
Relative Volume:
0.25
時価総額：
$3.52M
収益：
$31,800
当期純損益:
$-37.83M
株価収益率:
-2.3662
EPS:
-0.71
ネットキャッシュフロー:
$-30.64M
1週間 パフォーマンス:
-12.50%
1か月 パフォーマンス:
-65.00%
6か月 パフォーマンス:
-95.48%
1年 パフォーマンス:
-98.68%
1日の値動き範囲:
$1.68
$1.75
1週間の範囲:
$1.67
$1.955
52週間の値動き範囲:
$1.67
$205.60
Eyenovia Inc Stock (EYEN) Company Profile
EYEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
1.68 | 3.52M | 31,800 | -37.83M | -30.64M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-03-01 | 開始されました | Northland Capital | Outperform |
| 2020-02-03 | ダウングレード | Oppenheimer | Outperform → Perform |
Eyenovia Inc (EYEN) 最新ニュース
FY2025 EPS Estimates for Eyenovia Boosted by HC Wainwright - Defense World
Eyenovia Inc’s (EYEN) Stock: A -58.29% Simple Moving Average for the Past 20 Days - The News Heater
Wainwright maintains neutral Eyenovia stock, $2 target - MSN
Wainwright maintains neutral Eyenovia stock, $2 target By Investing.com - Investing.com Canada
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire
The Attractiveness of Investing In Eyenovia Inc (EYEN) is Growing - Knox Daily
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - Marketscreener.com
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan
Eyenovia enacts reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Eyenovia enacts reverse stock split to meet Nasdaq requirements - Investing.com
Eyenovia (NASDAQ:EYEN) Shares to Reverse Split on Monday, February 3rd - Defense World
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Eyenovia approves 1-for-80 reverse stock split; shares slip - MSN
Eyenovia Announces 1-for-80 Reverse Stock Split - The Manila Times
Major Shake-up at Eyenovia: Massive 80:1 Share Consolidation Coming February - StockTitan
Eyenovia, Inc. Approves 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance - Nasdaq
Eyenovia shareholders approve reverse stock split and additional stock reserve - MSN
Eyenovia shareholders approve reverse stock split and additional stock reserve By Investing.com - Investing.com Australia
Financial Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) & Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia secures $1 million from warrant repricing and exercise - MSN
Eyenovia secures $1 million from warrant repricing and exercise By Investing.com - Investing.com Canada
SEC Form 424B3 filed by Eyenovia Inc. - Quantisnow
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote 'FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - The Manila Times
Eyenovia Announces Leading Proxy Advisory Firms, ISS and - GlobeNewswire
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - GlobeNewswire Inc.
Ladenburg Thalmann Downgrades Eyenovia (EYEN) - MSN
Geode Capital Management LLC Increases Stock Position in Eyenovia, Inc. (NASDAQ:EYEN) - Defense World
Deal Dispatch: TD Bank To Sell Charles Schwab Stake? Eyenovia, Smart Share Hit Auction Block - Benzinga
Mydriasis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Eyenovia Eyes Cost-Cutting Measures Amid Disappointing Study Results - MPO-mag
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Eyenovia explores strategic alternatives, advances Optejet device By Investing.com - Investing.com Nigeria
Eyenovia Hires Financial Adviser Amid Business Review - MarketWatch
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives - GlobeNewswire
Eyenovia explores strategic alternatives, advances Optejet device - Investing.com
Eyenovia Explores Strategic Alternatives, Accelerates Optejet Device Development Plans - StockTitan
Eyenovia Inc (EYEN) 財務データ
収益
当期純利益
現金流量
EPS
Eyenovia Inc (EYEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):